119 related articles for article (PubMed ID: 17074681)
41. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases.
Janossy G; Coustan-Smith E; Campana D
Leukemia; 1989 Mar; 3(3):170-81. PubMed ID: 2465463
[TBL] [Abstract][Full Text] [Related]
42. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
[TBL] [Abstract][Full Text] [Related]
43. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias.
Zhang X; Lin Z; Kim I
J Korean Med Sci; 2003 Dec; 18(6):804-8. PubMed ID: 14676435
[TBL] [Abstract][Full Text] [Related]
44. Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5.
Pongubala JM; Northrup DL; Lancki DW; Medina KL; Treiber T; Bertolino E; Thomas M; Grosschedl R; Allman D; Singh H
Nat Immunol; 2008 Feb; 9(2):203-15. PubMed ID: 18176567
[TBL] [Abstract][Full Text] [Related]
45. Assessment of monocytic component in acute myelomonocytic and monocytic/monoblastic leukemias by a chemiluminescent assay.
da Fonseca LM; Brunetti IL; Campa A; Catalani LH; Calado RT; Falcão RP
Hematol J; 2003; 4(1):26-30. PubMed ID: 12692517
[TBL] [Abstract][Full Text] [Related]
46. Frequent aberration of FHIT gene expression in acute leukemias.
Iwai T; Yokota S; Nakao M; Nakazawa N; Taniwaki M; Kimura T; Sonoda Y; Kaneko H; Okuda T; Azuma H; Oka T; Takeda T; Watanabe A; Kikuta A; Asami K; Sekine I; Matsushita T; Tsuchiya T; Mimaya J; Koizumi S; Ohta S; Miyake M; Takaue Y; Iwai A; Fujimoto T
Cancer Res; 1998 Nov; 58(22):5182-7. PubMed ID: 9823330
[TBL] [Abstract][Full Text] [Related]
47. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia.
Coustan-Smith E; Behm FG; Hurwitz CA; Rivera GK; Campana D
Leukemia; 1993 Jun; 7(6):853-8. PubMed ID: 7684798
[TBL] [Abstract][Full Text] [Related]
48. CD163: a specific immunohistochemical marker for acute myeloid leukemia with monocytic differentiation.
Garcia C; Gardner D; Reichard KK
Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):417-21. PubMed ID: 18542032
[TBL] [Abstract][Full Text] [Related]
49. Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia.
Rice AM; Holtz KM; Karp J; Rollins S; Sartorelli AC
Leuk Res; 2004 Nov; 28(11):1227-37. PubMed ID: 15380350
[TBL] [Abstract][Full Text] [Related]
50. CD22 regulates early B cell development in BOB.1/OBF.1-deficient mice.
Samardzic T; Gerlach J; Muller K; Marinkovic D; Hess J; Nitschke L; Wirth T
Eur J Immunol; 2002 Sep; 32(9):2481-9. PubMed ID: 12207332
[TBL] [Abstract][Full Text] [Related]
51. GATA-1, GATA-2, and stem cell leukemia gene expression in acute myeloid leukemia.
Shimamoto T; Ohyashiki JH; Ohyashiki K; Kawakubo K; Kimura N; Nakazawa S; Toyama K
Leukemia; 1994 Jul; 8(7):1176-80. PubMed ID: 8035609
[TBL] [Abstract][Full Text] [Related]
52. Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers.
Hansson M; Jerkeman M; Dictor M
Eur J Haematol; 2007 Aug; 79(2):159-65. PubMed ID: 17635241
[TBL] [Abstract][Full Text] [Related]
53. PAX5 expression in nonhematopoietic tissues. Reappraisal of previous studies.
Morgenstern DA; Hasan F; Gibson S; Winyard P; Sebire NJ; Anderson J
Am J Clin Pathol; 2010 Mar; 133(3):407-15. PubMed ID: 20154279
[TBL] [Abstract][Full Text] [Related]
54. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
55. EBF1 drives hallmark B cell gene expression by enabling the interaction of PAX5 with the MLL H3K4 methyltransferase complex.
Bullerwell CE; Robichaud PP; Deprez PML; Joy AP; Wajnberg G; D'Souza D; Chacko S; Fournier S; Crapoulet N; Barnett DA; Lewis SM; Ouellette RJ
Sci Rep; 2021 Jan; 11(1):1537. PubMed ID: 33452395
[TBL] [Abstract][Full Text] [Related]
56. BOB.1/OBF.1 is required during B-cell ontogeny for B-cell differentiation and germinal center function.
Betzler AC; Fiedler K; Hoffmann TK; Fehling HJ; Wirth T; Brunner C
Eur J Immunol; 2022 Mar; 52(3):404-417. PubMed ID: 34918350
[TBL] [Abstract][Full Text] [Related]
57. [Fluorescence in situ hybridization studies on a myeloid leukemia patient with ins(8;21)(q22;q22.1q22.3)].
Wu YF; Xue YQ; Bai SX; Zhang J; Yao L; Wang Y; Qiu HY; Shen J; Pan JL; Ma QF
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):203-6. PubMed ID: 19350517
[TBL] [Abstract][Full Text] [Related]
58. B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages.
Hodawadekar S; Yu D; Cozma D; Freedman B; Sunyer O; Atchison ML; Thomas-Tikhonenko A
Exp Cell Res; 2007 Jan; 313(2):331-40. PubMed ID: 17098231
[TBL] [Abstract][Full Text] [Related]
59. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia.
Nebral K; König M; Harder L; Siebert R; Haas OA; Strehl S
Br J Haematol; 2007 Oct; 139(2):269-74. PubMed ID: 17897302
[TBL] [Abstract][Full Text] [Related]
60. [Cellular immunophenotypes in 97 adults with acute leukemia].
Piedras J; López-Karpovitch X; Cárdenas MR
Rev Invest Clin; 1997; 49(6):457-64. PubMed ID: 9528305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
